TB SCRIPT Trial Project

TB Screening Improves Preventive Therapy Uptake Trial (TB-SCRIPT)

Study Period: November 2020- March 2025

Overview

Tb-script is a groundbreaking research initiative to evaluate the clinical impact of Point-of-Care (POC) C-reactive protein (CRP) based TB screening on immediate and longer-term outcomes of individuals living with HIV. This pragmatic single-blinded, randomised-controlled Phase III trial is conducted at four prominent clinics in Kampala, Uganda. 

Aims of the trial. 

Overall aim: The overall objective of this randomised trial is to evaluate the effectiveness and cost-effectiveness of POC CRP-based TB screening 

Specific aims of the trial

Aim 1: Compare the impact of point-of-care C-reactive protein (POC CRP)- vs. symptom-based TB screening on 2-year patient outcomes.

Aim 2: Compare the impact of POC CRP-   vs symptom-based TB screening on TB preventive therapy (TBPT) uptake and TB case detection.

Aim 3: Compare cost, cost-effectiveness, and projected epidemiological impact of POC CRP- vs. symptom-based TB screening.

Who is funding the trial?

The National Heart Lung and Blood Institute of the National Institute of Health, USA funds the trial. 

Research outputs. 

  1. Chaisson LH, Semitala FC, Mwebe S, et al. Transaminitis prevalence among HIV-infected adults eligible for tuberculosis preventive therapy. Aids. 2022;36(11):1591-5.
  2. Semitala FC, Chaisson LH, Dowdy DW, et al. Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomised controlled trial. Trials. 2022;23(1):399.
  3. Chaisson LH, Semitala FC, Nangobi F, et al. Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and three months’ weekly isoniazid-rifapentine. Aids. 2023;37(7):1097-101.

Further information can be accessed in the protocol at the reference below

Semitala FC, Chaisson LH, Dowdy DW, et al. Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomised controlled trial. Trials. 2022;23(1):399.

Study Site: Kawaala KCCA Health Centre IV, Kitebi KCCA Health Centre III, TASO Mulago and Mulago Immune Suppression Syndrome (Mulago ISS Clinic)

Collaborators: University of California San Francisco (UCSF)

Principal Investigators: PI- Joselyn Rwebembera

Study Sponsor: National Heart Lung and Blood Institute of the National Institute of Health (NIH), USA

Avantage
Headquarters
Visualize quality intellectual capital without superior collaboration and idea sharing installed base portals.
Our locations
Where to find us?
https://www.idrc-uganda.org/wp-content/uploads/2020/04/img-footer-map.png
Get in touch
Avantage Social links
Taking seamless key performance indicators offline to maximise the long tail.
Avantage
Headquarters
Visualize quality intellectual capital without superior collaboration and idea sharing installed base portals.
Our locations
Where to find us?
https://www.idrc-uganda.org/wp-content/uploads/2020/04/img-footer-map.png
Get in touch
Avantage Social links
Taking seamless key performance indicators offline to maximise the long tail.